Table 1.
Strategies of different companies using PD-L1 expression level as a companion diagnosis (adapted from information released by College of American pathologist).
| Agent | Atezolizumab (Genetech/Roche) | Nivolumab (BMS) | Pembrolizumab (Merck) | Durvalumab (AZ) | |
|---|---|---|---|---|---|
| Target | PD-L1 | PD-1 | PD-1 | PD-1 | |
| PD-L1 IHC antibody | Ventana SP142 | Dako 28-8 | Dako 22C3 | Ventana SP263 | |
| Cell types and scoring method | NSCLC-TC/IC | NSCLC-TC | NSCLC-TC | NSCLC-TC | |
| UBC-TC/IC | |||||
| UBC-IC | |||||
| Cut-off definitions in NSCLC | TC or IC≥1% | TC ≥1% | TC =1%-49% | TC ≥25% | |
| TC or IC≥5% | TC ≥5% | TC ≥50% | |||
| TC ≥50% or IC≥10% | TC ≥10% | ||||
| Cut-off definitions in UBC | IC≥10%; IC≥5%; IC≥1% | NA | ≥1% TC or any stromal staining | NA | |
NA, Not Available.